APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Introduction: Pathogenesis of Alzheimer's disease (AD) in apolipoprotein E ε4 (APOE ε4) carriers remains unclear. We hypothesize that APOE isoforms have differential effects on synaptic function. Methods: We compared levels of CSF neurogranin (Ng) between APOE ε4 carriers and noncarriers in 399 subjects with normal cognition, mild cognitive impairment (MCI), and AD. We examined associations between Ng levels and age, education, gender, CSF‐Aβ42, and tau protein. Results: Neurogranin levels were significantly higher in APOE ε4 carriers compared to APOE ε4 noncarriers with MCI. Levels of Ng between the APOE ε4 carriers and APOE ε4 noncarriers with AD did not differ. Ng levels were correlated with MMSE and levels of tau and Aβ42. Discussion: Significantly higher CSF Ng levels in APOE ε4 carriers with MCI may reflect synaptic injury underlying early cognitive impairment. Neurogranin may be an early biomarker of AD and important for disease diagnosis and timing of intervention in APOE ε4 carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 1×
“Emerging evidence suggests that A β - induced synaptic dysfunction is dependent on the elevation of cytoplasmic Ca 2+ and N-methyl-D-aspartate (NMDA) receptor-mediated activity, and this process results in dendritic spine loss [32–34].”
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 1×
“APOE ε4 carriers with AD or amnestic mild cognitive impairment (MCI) have lower b-amyloid 42 (Ab42), elevated total tau (t-tau), and phospho-tau (p-tau) in cerebrospinal fluid (CSF), compared to APOE ε4 noncarriers [2].”
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
Cited by
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
“• SNAP-25 was elevated even in amyloid PET-negative individuals 249 , whereas neurogranin was not significantly associated with the APOE genotype after controlling for CSF Aβ and pTau levels 250 .”
Neurogranin as a predictor of memory and executive function decline in MCI patients
Headley, A., De Leon-Benedetti, A., Dong, C., Levin, B., Loewenstein, D., Camargo, C., Rundek, T., Zetterberg, H., Blennow, K., Wright, C. B., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005057 · Cited by 62
Self-citationNeurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia
Willemse, E. A. J., Sieben, A., Somers, C., Vermeiren, Y., De Roeck, N., Timmers, M., Van Broeckhoven, C., De Vil, B., Cras, P., De Deyn, P. P., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.002 · Cited by 34
APOE ε4 is associated with decreased synaptic density in cognitively impaired participants
He, K., Li, B., Wang, J., Wang, Y., You, Z., Chen, X., Chen, H., Li, J., Huang, Q., Guo, Q., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13775 · Cited by 29
Metadata
- Authors
- Sun, X., Dong, C., Levin, B., Crocco, E., Loewenstein, D., Zetterberg, H., Blennow, K., Wright, C. B., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-06-16
- Volume
- 12
- Issue
- 11
- Pages
- 1159-1166
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2440337417
- Cited by
- 42
- References
- 14
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2016.05.003
- The paper
- Sun, X., Dong, C., Levin, B., Crocco, E., Loewenstein, D., Zetterberg, H., Blennow, K., Wright, C. B., & Initiative, A. D. N. (2016). APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.05.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.